Pyxis Oncology’s (PYXS) “Outperform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report released on Friday,Benzinga reports. The brokerage currently has a $8.00 price objective on the stock, down from their previous price objective of $10.00.

A number of other brokerages have also issued reports on PYXS. William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Stephens began coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Thursday, November 21st. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $9.43.

Pyxis Oncology Stock Performance

NASDAQ PYXS opened at $1.69 on Friday. The company has a market capitalization of $100.50 million, a P/E ratio of -1.64 and a beta of 1.00. The company has a fifty day moving average of $2.93 and a 200-day moving average of $3.29. Pyxis Oncology has a 52-week low of $1.49 and a 52-week high of $6.85.

Insider Activity

In related news, CFO Pamela Ann Connealy acquired 88,850 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were purchased at an average cost of $1.96 per share, with a total value of $174,146.00. Following the completion of the acquisition, the chief financial officer now directly owns 1,199,143 shares of the company’s stock, valued at $2,350,320.28. This represents a 8.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.80% of the company’s stock.

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC grew its position in shares of Pyxis Oncology by 275.0% in the third quarter. Barclays PLC now owns 64,089 shares of the company’s stock valued at $235,000 after purchasing an additional 46,997 shares during the period. Geode Capital Management LLC raised its position in shares of Pyxis Oncology by 5.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock valued at $3,982,000 after buying an additional 57,016 shares during the period. Public Employees Retirement System of Ohio acquired a new position in shares of Pyxis Oncology in the 3rd quarter valued at $107,000. XTX Topco Ltd raised its stake in shares of Pyxis Oncology by 133.6% in the 3rd quarter. XTX Topco Ltd now owns 84,771 shares of the company’s stock valued at $311,000 after acquiring an additional 48,481 shares during the period. Finally, Jane Street Group LLC lifted its stake in Pyxis Oncology by 40.8% during the third quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock worth $182,000 after purchasing an additional 14,349 shares in the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.